《慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2024年版)》解读
Interpretiation of consensus on the diagnosis and management of chronic graft-versus-host disease in China(2024)
王筱淇 1张曦1
作者信息
- 1. 陆军军医大学第二附属医院血液病医学中心,全军/重庆市临床重点专科,血液病与微环境重庆市重点实验室,创伤与化学中毒全国重点实验室(重庆,400037)
- 折叠
摘要
慢性移植物抗宿主病(chronic graft-versus-host disease,cGVHD)严重影响患者的生存率和生活质量.近年来,随着临床研究的不断推进和深入,cGVHD在诊断、防治等方面取得了显著进展.为在全国范围内推广规范化诊疗,结合国内外最新研究和指南,中华医学会血液学分会造血干细胞应用学组对《慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版)》进行了修订及更新,出版《慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2024年版)》(简称新版共识).本文旨在梳理和解读新版共识的更新要点,以更好地指导临床实践.
Abstract
Chronic graft versus-host disease(cGVHD)significantly impacts patients'survival rates and quali-ty of life.In recent years,substantial progress has been made in the diagnosis,prevention,and treatment of cGVHD,driven by ongoing and in-depth clinical research.To promote standardized diagnosis and treatment na tionwide,the Hematopoietic Stem Cell Transplantation Group of the Chinese Society of Hematology has revised and updated the"diagnosis and management of chronic graft-versus-host disease(2021)"by incorporating the lat-est domestic and international studies and guidelines,which is the publication of the"consensus on the diagnosis and management of chronic graft-versus-host disease in China(2024)"(hereafter referred to as the"New Consen-sus").This paper aims to review and interpret the key updates in the New Consensus to better guide clinical appli-cation and practice.
关键词
慢性移植物抗宿主病/规范化诊疗/新版共识Key words
chronic graft-versus-host disease/standardized diagnosis and treatment/New Consensus引用本文复制引用
基金项目
国家重点研发计划干细胞研究与器官修复重大专项(2022YFA1103300)
国家重点研发计划干细胞研究与器官修复重大专项(2022YFA1103304)
国家自然科学基金国际交流合作重点项目(82020108004)
陆军军医大学第二附属医院学科人才建设项目(2022YQB004)
陆军军医大学第二附属医院学科人才建设项目(2022XKRC001)
出版年
2024
NETL
NSTL
万方数据